Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of “Moderate Buy” from Analysts

Biogen Inc. (NASDAQ:BIIB) has received a consensus recommendation of “Moderate Buy” from the thirty-one analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $218.1481.

A number of research analysts recently issued reports on BIIB shares. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $214.00) on shares of Biogen in a report on Friday, May 15th. Argus upgraded shares of Biogen to a “hold” rating in a report on Thursday, April 9th. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. HSBC restated a “reduce” rating and issued a $157.00 price objective on shares of Biogen in a research report on Monday. Finally, Morgan Stanley dropped their price objective on Biogen from $224.00 to $222.00 and set an “equal weight” rating on the stock in a research note on Wednesday.

Institutional Investors Weigh In On Biogen

A number of hedge funds have recently modified their holdings of the business. Reflection Asset Management acquired a new position in shares of Biogen in the 4th quarter valued at approximately $25,000. WPG Advisers LLC raised its holdings in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the period. First Horizon Corp bought a new position in Biogen in the fourth quarter valued at approximately $30,000. WFA of San Diego LLC bought a new position in Biogen in the second quarter valued at approximately $32,000. Finally, Root Financial Partners LLC boosted its holdings in shares of Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 2.6%

NASDAQ:BIIB opened at $200.36 on Thursday. Biogen has a 1-year low of $121.05 and a 1-year high of $219.72. The business’s 50-day moving average price is $197.84 and its two-hundred day moving average price is $187.82. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $29.58 billion, a price-to-earnings ratio of 21.50 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts expect that Biogen will post 13.95 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.